Trial Profile
A Randomized Three-Arm, Single-dose, Two-period Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Lenvatinib
- Indications Biliary cancer; Endometrial cancer; Liver cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Renal cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Inc
- 14 Jun 2016 New trial record